Fair value · KAZIA THERAPEUTICS LTD (KZIA) · updated 2026-10-24 · from 20-F FY2025
KAZIA THERAPEUTICS trades at $7.81. We are not reading assumptions out of that price: this is a depositary receipt whose filed share count matches neither the ordinary share count nor the number of receipts outstanding, so we cannot show its per-share figures are on the same scale as our price and these methods are withheld.
Everything below is unaffected: the filed statements, the filing they came from, and KZIA’s growth history are all as reported.
At least two methods need a usable value to draw a range with these inputs.
Range with preset inputs
No preset range for this company yet.
The two ranges are identical because every input sits on a preset.
We don’t tell you what KZIA is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has KZIA’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.
Discounted cash flow
N/A
This is a depositary receipt whose filed share count matches neither the ordinary share count nor the number of receipts outstanding, so we cannot show its per-share figures are on the same scale as our price and these methods are withheld.
Preset inputs — revenue-driven DCF from the latest filing
Implied by today’s price
This is a depositary receipt whose filed share count matches neither the ordinary share count nor the number of receipts outstanding, so we cannot show its per-share figures are on the same scale as our price and these methods are withheld.
Not solvable from the price — This is a depositary receipt whose filed share count matches neither the ordinary share count nor the number of receipts outstanding, so we cannot show its per-share figures are on the same scale as our price and these methods are withheld. Showing preset inputs.
This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what KZIA has actually filed, and the AI chat will reason it through with you.
Your inputs
Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.
Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.
-20.0%60.0%
How long stage-1 growth lasts.
1 yrs10 yrs
Slower growth after stage 1, before the terminal phase.
-20.0%30.0%
0 yrs10 yrs
Growth forever after the two stages. Above ~3% is rarely justified.
0.0%5.0%
The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.
